



## Request under Freedom of Information Act 2000

Thank you for your request for information which we received on 15 November 2022.

I am pleased to confirm the following.

## Q1. Please provide the total number of patients treated in the last 3 months with any systemic anti-cancer therapy for:

- Oesophageal cancer (any type or stage)
- Oesophageal adenocarcinoma (any stage)
- Oesophageal squamous cell carcinoma (any stage)
- Gastric cancer (any type or stage)
- Cancer of the gastro-oesophageal junction (any stage)

No. of patients between 1/8/22 – 31/10/22 diagnosed with 'C15 - Malignant neoplasm of oesophagus' Treated with chemotherapy, based on treatment start date.

Count of Hospital Number - Total 14

## Q2. How many patients were treated in the past 3 months for gastric and gastrooesophageal junction cancer (any stage) with:

- CAPOX (Capecitabine with Oxaliplatin) 0
- FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) 2
- Lonsurf (Trifluridine tipiracil) 0
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) 0
- Any other systemic anti-cancer therapy
- Palliative care only

## Q3. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:

- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) 0
- Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with

As a teaching hospital, we conduct education and research to improve healthcare for our patients. During your visit students may be involved in your care, or you may be asked to participate in a clinical trial. Please speak to your doctor or nurse if you have any concerns.

Chief Executive: Professor Joe Harrison Chair: Alison Davis 5-Fluorouracil or Capecitabine)

- Nivolumab monotherapy 5
- Nivolumab and Ipilimumab 0
- Any other systemic anti-cancer therapy 5
- Palliative care only

You are advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely,

Freedom of Information Co-ordinator For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the 'Re-use of Public Sector Information Regulations' and best practice.